Transparency Market Research (TMR) has published a new
report titled, “Allergy
relieving Eye Drops Market - Global Industry Analysis, Size, Share, Growth,
Trends, and Forecast, 2018–2026”. According to the report, the allergy-relieving
eye drops market was valued at US$ 1250.0 Mn in 2017. The
market is anticipated to reach US$ 1,930.0 Mn by 2026, expanding at a CAGR of
5.0% from 2018 to 2026. Rise in number of geriatric patients, increase in
awareness regarding minor eye disorders, and high unmet medical needs are
expected to augment the global market from 2018 to 2026. The allergy-relieving
eye drops market is projected to expand owing to an increase in the prevalence
of eye-related disorders among the population, demand for better treatments,
and development of healthcare infrastructure in various economies.
Request Brochure –
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14933
Increasing
geriatric population and rising awareness regarding eye diseases
According
to data published by United Nations Department of Economics and Social Affairs,
the global geriatric population is expected to double by the end of 2050 and is
projected to reach nearly 2.1 billion. This increasing geriatric population is
prone to significant risk of eye-related disorders, including blindness. Public
awareness regarding common eye conditions is increasing in developing
countries, leading to early diagnosis and treatment of eye diseases.
Furthermore, a large number of organizations are dedicated to fight blindness,
restore vision, and create awareness regarding eye health. National Eye
Institute, National Association for Visually Handicapped, National Federation
of the Blind, and Prevent Blindness are a few eye health organizations
concerned with the prevention of eye diseases.
Request COVID Analysis on Allergy Relieving Eye Drops Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=14933
Increase
in prevalence and incidence rates of eye-related disorders
According
to World Health Organization (WHO), there are 285 million visually impaired
people globally, approximately 90% of them living in low to middle income
countries. Furthermore, approximately 95 million people suffer from cataract
and 20 million suffer from various eye conditions, including glaucoma, muscular
degeneration, infections, and childhood-related conditions. Significant rise in
incidence of eye-related diseases, especially in developed countries, is
anticipated to drive the allergy-relieving eye drops market between 2018 and
2026.
Patients
undergoing open angle glaucoma and AMD in the U.S., were 2.7 Mn and 2.1 Mn,
respectively. This number is projected to increase to 3.3 Mn and 2.5 Mn,
respectively, by 2020. Increasing patient pool in developing countries as well
as developed countries is estimated to propel healthcare spending for eye
treatments in these countries and drive the allergy-relieving eye drops market.
High unmet needs in patients with
ocular allergy
The
currently available treatment options are insufficient, as almost 30% to 40% of
patients suffer from persistent allergic inflammation due to incomplete
response to antihistamines. Therefore, a large proportion of patients with
ocular allergy have high unmet needs, providing an opportunity for the
development of novel treatment for eye-related allergies. According to an
article published in NCBI, approximately 20% of the total population suffers
from some form of allergic conjunctivitis and significant proportion of
patients experience chronic allergy due to low response to existing therapies.
Request Customization on Allergy
Relieving Eye Drops Market Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=14933
Antihistamines
segment dominates the global market due to its choice as first line of
treatment for allergic conjunctivitis
In terms of
drug class, antihistamines was a highly attractive segment of the global
allergy-relieving eye drops market, followed by non-steroidal anti-inflammatory
drugs and vasoconstrictors segments. This is attributable to the preference for
antihistamines as the first line of treatment for allergic conjunctivitis.
According to a study published by NCBI, dual-acting antihistamines combined
with mast cell stabilizers are considered the first-line therapeutics for
allergic conjunctivitis, as they provide acute relief against signs and
symptoms and block persistent inflammation to promote regression of ocular
allergy. Moreover, they are well-tolerated for chronic usage in case of
persistent ocular allergies.
North America dominates the global
market owing to significant funding from government in order to improve quality
of life for persons suffering from Alzheimer’s disease
North
America dominates the overall allergy-relieving eye drops market due to a large
patient pool, high cost of specialty branded drugs, and increasing patient
pool. The region is estimated to maintain its dominance of the global market
during the forecast period. According to an article published by The Journal of
Allergy and Clinical Immunology, up to 40% of the U.S. population experiences
ocular allergy at least once in their lifetime. Moreover, rising healthcare
expenditure and increasing investments are key factors that are anticipated to
boost the allergy-relieving eye drops market in the next few years. The
allergy-relieving eye drops market in Asia Pacific is projected to expand at a
notable CAGR due to increasing awareness regarding allergy-relieving eye drops
in developing countries and government initiatives introduced in the region.
Buy Allergy Relieving Eye Drops Market Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=14933<ype=S
Investments
by key players is driving the global allergy-relieving eye drops market.
Key players
dominating the allergy-relieving eye drops market include Allergan Plc.,
Johnson & Johnson Services, Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd.,
Novartis AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc., and
Santen Pharmaceutical Co., Ltd.
About Us
Transparency
Market Research is a global market intelligence company, providing global
business information reports and services. Our exclusive blend of quantitative
forecasting and trends analysis provides forward-looking insight for thousands
of decision makers. Our experienced team of Analysts, Researchers, and
Consultants, use proprietary data sources and various tools and techniques to
gather, and analyze information.
Our data
repository is continuously updated and revised by a team of research experts,
so that it always reflects the latest trends and information. With a broad
research and analysis capability, Transparency Market Research employs rigorous
primary and secondary research techniques in developing distinctive data sets
and research material for business reports.
Contact
Transparency
Market Research,
90 Sate
Street, Suite 700,
Albany, NY
12207
Tel:
+1-518-618-1030
USA -
Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com
